menu

MENU

繁體中文

Contact Us

Menu

Menu

Company

Introduction
Team & Board of Directors
Partners
Investors
Latest News

R&D Pipeline

Overview
Intranasal Vaccines
Asthma Immunotherapy
Respiratory Antiviral Immunotherapy

Company

Introduction

Team & Board of Director

Partners

Investors

Latest News

R&D Pipeline

Overview

Intranasal Vaccines

Asthma Immunotherapy

Respiratory Antiviral Immunotherapy

Contact us

Latest News

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form

February 25, 2022

Phase Ib/IIa Clinical Trial of AD17002-AI for House Dust Mite-Induced Allergic Rhinitis Completes Testing and 8-Week Hospital Follow-up for All Subjects in Cohort 2 (Mid-Dose Group).

Updates

December 10, 2021

【環球生技月刊】鎖定輕症！昱厚鼻噴新冠藥 申請食藥署IIa期人體臨床試驗

Press

September 28, 2021

【工商時報B6】昱厚新冠新藥 擬進軍中東

Press

September 28, 2021

【經濟日報C6】昱厚攻新冠藥 插旗巴基斯坦市場

Press

September 27, 2021

The Company Signs Memorandum of Understanding (MOU) with Macter International Limited (Pakistan) for the Licensing and Distribution of Investigational COVID-19 Drug AD17002-SC in Pakistan.

Updates